Article View: ba.consumers
Article #12281ALERT: Consumer Access to Low-Cost Generic Drugs Jeopardized
From: Charles Bain
Date: Fri, 21 Jul 1995 00:00
Date: Fri, 21 Jul 1995 00:00
43 lines
2749 bytes
2749 bytes
Coalition Formed to Urge Revision of FDA Ruling
http://policy.net/gdec
Consumer, senior citizen and healthcare groups and pharmaceutical firms
have joined together as the Generic Drug Equity Coalition to urge
consumers to take action to ensure access to low-cost generic drugs. The
groups include Public Citizen, U.S. PIRG, the National Council on Aging,
National Women�s Health Network and pharmaceutical industry companies
such as Novopharm, Mylan and Geneva Pharmaceuticals and many others.
Generic versions of some of this country�s most widely prescribed
medicines will be kept off of the market due to a Food and Drug
Administration (FDA) interpretation of a General Agreement on Trade and
Tariffs (GATT) Treaty provision which extends brand name drug patents.
Generic forms of popular drugs will not be certified until the
GATT-extended patents on the brand name versions expire. The FDA�s
decision will cost American consumers billions of dollars.
The Generic Drug Equity Coalition is urging Congress to pass legislation
to require the FDA to use pre-GATT patent expiration dates to determine
when generic drugs can be certified for marketing and available to
consumers.
Consumers, healthcare professionals and others can learn more about this
issue at the Generic Drug Equity Coalition�s WWW Home Page; the Internet
address is http://policy.net/gdec. If, after reviewing this material,
concerned individuals agree that Congress should act to give consumers
access to low-cost generic versions of such drugs as Zantac and Capozide,
they can use an interactive support form to contact their Senators and
Representative that will automatically forward an e-mail message. For
those who prefer to send their own submission, a sample e-mail letter is
provided for consideration.The Coalition may also be reached by e-mail at
gdec@policy.net, or by phone at (202) 842-1656.
Please take a few minutes to review this issue and contact your Senators
and Representative. Billions of consumer dollars are at stake. Thanks
for your support.
Charles Bain
Generic Drug Equity Coalition
WWW: http://policy.net/gdec
E-mail: gdec@policy.net
Technical Details
Message-ID:
<3upa3t$329@news.cais.com>Path:
arc1-ca.pugleaf.net!unknown!not-for-mailShow Full Headers
Complete Article Headers
X-Google-Language: ENGLISH,ASCII X-Google-Thread: 106595,f2669101a27cffd7,start X-Google-Attributes: gid106595,public From: Charles Bain <gdec@policy.net> Subject: ALERT: Consumer Access to Low-Cost Generic Drugs Jeopardized Date: 1995/07/21 Message-ID: <3upa3t$329@news.cais.com> X-Deja-AN: 106734234 content-type: text/plain; charset=iso-8859-1 organization: Generic Drug Equity Coalition mime-version: 1.0 newsgroups: ba.consumers x-mailer: Mozilla 1.2b2 (Windows; I; 16bit)